

RESEARCH ARTICLE

Comparative compositional and functional analyses of *Bothrops moojeni* specimens reveal several individual variations

Weslei da Silva Aguiar^{1,2}, Nathália da Costa Galizio^{1,2}, Caroline Serino-Silva^{1,2}, Sávio Stefanini Sant'Anna¹, Kathleen Fernandes Grego¹, Alexandre Keiji Tashima³, Erika Sayuri Nishiduka³, Karen de Moraes-Zani^{1,2}, Anita Mitico Tanaka-Azevedo^{1,2*}

1 Laboratório de Herpetologia, Instituto Butantan, São Paulo, Brasil, **2** Interunidades em Biotecnologia, Universidade de São Paulo, Instituto de Pesquisas Tecnológicas, Instituto Butantan, São Paulo, Brasil, **3** Departamento de Bioquímica, Universidade Federal de São Paulo, São Paulo, Brasil

* amt.azevedo@uol.com.br



OPEN ACCESS

Citation: Aguiar WdS, Galizio NdC, Serino-Silva C, Sant'Anna SS, Grego KF, Tashima AK, et al. (2019) Comparative compositional and functional analyses of *Bothrops moojeni* specimens reveal several individual variations. PLoS ONE 14(9): e0222206. <https://doi.org/10.1371/journal.pone.0222206>

Editor: Luis Eduardo M. Quintas, Universidade Federal do Rio de Janeiro, BRAZIL

Received: June 1, 2019

Accepted: August 23, 2019

Published: September 12, 2019

Copyright: © 2019 Aguiar et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript and its Supporting Information files.

Funding: This work was supported by grants from Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) (2014/11108-0, 2016/03839-0, 2017/01890-0 to AMT-A, 2017/16908-2 to KdM-Z, 2017/20106-9 to AKT, 2018/14724-4, 2018/20651-0 to WdSA and 2018/25786-0 to AMT-A), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Financiadora de Estudos e

Abstract

Snake venoms are complex protein mixtures with different biological activities that can act in both their preys and human victims. Many of these proteins play a role in prey capture and in the digestive process of these animals. It is known that some snakes are resistant to the toxicity of their own venom by mechanisms not yet fully elucidated. However, it was observed in the Laboratory of Herpetology of Instituto Butantan that some *Bothrops moojeni* individuals injured by the same snake species showed mortalities caused by envenoming effects. This study analyzed the biochemical composition of 13 venom and plasma samples from *Bothrops moojeni* specimens to assess differences in their protein composition. Application of sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) showed distinct venom protein profiles, but very homogeneous plasma profiles. Western Blotting (WB) was performed with plasma samples, which were submitted to incubation with the respective venom. Some individuals showed an immunorecognized band zone around 25 kDa, indicating interaction between the same individual plasma and venom proteins. Crossed-WB assay using non-self-plasma and venom showed that this variability is due to venom protein composition instead of plasma composition. These venoms presented higher caseinolytic, collagenolytic and coagulant activities than the venoms without these regions recognized by WB. Mass spectrometry analyses performed on two individuals revealed that these individuals present, in addition to higher protein concentrations, other exclusive proteins in their composition. When these same two samples were tested *in vivo*, the results also showed higher lethality in these venoms, but lower hemorrhagic activity than in the venoms without these regions recognized by WB. In conclusion, some *Bothrops moojeni* specimens differ in venom composition, which may have implications in envenomation. Moreover, the high individual venom variability found in this species demonstrates the importance to work with individual analyses in studies involving intraspecific venom variability and venom evolution.

Projetos, and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Introduction

Snake venoms are probably one of the most complex of all known venoms, and are the most studied animal toxins since last century [1–4] to the present day [5–9]. Venoms are a highly effective adaptive trait underlying the evolution of advanced snakes, which have changed the way of prey capture from mechanical (constriction) to chemical (venom), and this innovation has played an important role in the diversification of these animals [10,11]. Snake venoms are subjected to Darwinian evolution [12,13] and the variability of these toxic secretions provides snakes with adaptability to different ecological niches [14]. The variability of venom composition and activities has been reported in numerous studies, and it can be observed at different levels, such as species, subspecies, populations, and individuals [15–20]. The composition of venoms results from multiple factors, and their inherent diversification is generally associated with environmental and ecological aspects [21].

Since the 18th century, it is known that snakes are resistant to their own venoms. The first study addressing natural venom immunity was conducted by Fontana [22] in 1781, who reported that “the venom of the viper is not venomous to its species”. However, several concepts were further established in the 19th century, including the one that the natural immunity is not species-specific [23] and can be found in other animals, such as several species of opossums, squirrels, mongooses, and hedgehogs [24–27]. This resistance is generally assigned to mutations in the gene encoding the target of the venom toxin, resulting in an insensitive target, and/or to the presence of neutralizing factors in the blood of resistant animals [28–30].

Bothrops species are responsible for over 90% of the notified snake accidents in Brazil [31], thus the epidemiology of this genus is of great medical and social importance [32]. Due to its clinical relevance, the most studied Brazilian snake species is *Bothrops jararaca*, and its venom and purified toxins have been comprehensively investigated. In addition, inhibitors from *B. jararaca* plasma and serum have been identified, isolated, and characterized, including phospholipase A₂ inhibitors (PLIs) [33], a thrombin inhibitor that also binds to thrombin-like venom toxins [34,35], and a metalloproteinase inhibitor (the anti-hemorrhagic factor Bj46a) [30]. It is believed that these molecules play an important physiologic role in the protection mechanism against self-envenomation and envenomation by other snake species.

Another species with high medical relevance in Brazil is *B. moojeni*, classified within Category 1 by the World Health Organization (WHO), corresponding to one of the species of highest medical importance, defined as “highly venomous snakes which are common or widespread and cause numerous snake-bites, resulting in high levels of morbidity, disability or mortality” [36]. This snake, popularly known as *caissaca*, is responsible for most of the snake-bites in the Central region of Brazil (Fig 1) [37]. Its venom composes the pool of five *Bothrops* species, namely *B. jararaca* (50%), *B. alternatus* (12.5%), *B. jararacussu* (12.5%), *B. moojeni* (12.5%) and *B. neuwiedi* (12.5%), used to produce the bothropic polyvalent F(ab')₂ antivenom (*soro antibotrópico*—SAB) by the Instituto Butantan (São Paulo, Brazil), using a method of hyperimmunization of horses. Due to the importance of the species from a medical standpoint, its venom proteome has been recently characterized. *B. moojeni* venom is composed mainly of snake venom metalloproteinases (SVMP) (36.5–39.8%), snake venom serine proteases (SVSP) (14.7–19.8%), phospholipases A₂ (PLA₂) (11.5–17.1%), L-amino acid oxidases (LAAO) (4.2–5.2%), and C-type lectins (CTL) (2.4–3.1%) Followed by less abundant toxins such as vascular endothelial growth factors (VEGF), bradykinin-potentiating peptides (BPP), cysteine-rich secretory protein (CRISP), and hyaluronidases, which together account for less than 15% of total venom proteins [38]. Reflecting its venom composition, the symptomatology caused by *B. moojeni* envenomation presents the classical local and systemic symptoms of bothropic




Fig 1. Geographic distribution of *B. jararaca* snakes used throughout this study. Orange dots represent female individuals and green triangles represent male ones.

<https://doi.org/10.1371/journal.pone.0222206.g001>

accidents, such as edema, ecchymosis, necrosis, blisters, spontaneous bleeding, and blood incoagulability [39].

Concerning plasmatic venom inhibitors, only two molecules have been described in *B. moojeni* plasma to date, both of them are PLIs: a γ -PLI, identified by molecular biology [40], and an α -PLI (BmjMIP), isolated and characterized from its plasma [41]. Interestingly, BmjMIP presents the ability to neutralize enzymatic, toxic and pharmacological activities of basic and acidic PLA₂ from *B. moojeni*, *B. pirajai* and *B. jararacussu* venom [41].

Given the background, the *B. moojeni* species represents an intriguing model, considering that a peculiarity observed in these animals is the high mortality caused by envenomation among individuals of this species, which is not observed in other snakes of this genus. In captivity, intraspecies envenoming accidents present visceral hemorrhage and necrosis in several spots, even in distal regions of the bite site (S1 Fig). This evidence indicates lack of a plasma defense mechanism against venom toxins and/or a peculiarity associated with individual venom composition. In summary, this comparative study describes the plasmatic venom inhibitors and the individual variability of venom composition and activities of 13 *B. moojeni* individuals.

Material and methods

Ethics statement

Swiss male mice weighing 18–22 g were obtained from the Center for Animal Breeding from Butantan Institute. Male and female individuals of *B. moojeni* snakes were obtained from the Laboratory of Herpetology of Instituto Butantan. All procedures involving animals were in accordance with the ethical principles for animal research adopted by the Brazilian Society of Animal Science and the National Brazilian Legislation n°.11.794/08. After *in vivo* tests, mice were euthanized using a CO₂ chamber, according to ethical parameters approved by the

Table 1. Biometric data and geographical origin of the *Bothrops moojeni* specimens used throughout this study. Individuals were identified after venom and plasma extractions. Identification: code used in this study to identify the individual; In captivity since (year): year when the individual came from nature to captivity; Weight (g): weight of each individual when samples were collected; Length (SVL) (cm): length of the individuals when samples were collected. SVL means *snout-vent-length*; Geographical origin: the place where the individual came from; Sex: M: male; F: female.

Identification	In captivity since (year)	Weight (g)	Length (SVL) (cm)	Geographic origin	Sex
Bm1	2002	1,605	134	Porto Primavera—SP	F
Bm2	2006	1,78	146	Araraquara—SP	F
Bm3	2009	985	140	Cuiabá—MT	F
Bm4	2010	655	135	Buritizal—SP	F
Bm5	2010	1,175	138	Patos de Minas—MG	F
Bm6	2012	490	114	Cajuru—SP	F
Bm7	2008	1,865	168	Palmas—TO	F
Bm8	2013	990	132	Patos de Minas—MG	F
Bm9	2013	520	110	Araraquara—SP	F
Bm10	2012	345	109	Araraquara—SP	M
Bm11	2013	440	108	Araraquara—SP	M
Bm12	2005	1,08	138	Palmas—TO	F
Bm13	2013	300	111	Araraquara—SP	M

<https://doi.org/10.1371/journal.pone.0222206.t001>

Brazilian College of Animal Experimentation (COBEA) and the Committee for the Ethical Use of Animals of Instituto Butantan (CEUAIB) (protocols n° 1304/14 and 1296/16).

Snakes

Thirteen adult *B. moojeni* snakes, ten males and three females, were used in this present study. Information regarding the snakes selected for this study is available on [Fig 1](#) and [Table 1](#). The snakes are maintained under controlled temperature and light/dark cycles (12:12), in individual acrylic boxes, with free access to water and fed on rodents (*Mus musculus* and/or *Rattus norvegicus*) once a month.

Mice

Male Swiss mice were housed in a temperature-controlled room under automatic 12h light/dark cycle. Food and water were freely available during the study period. The experiments were performed using five animals per group, with a total of 110 mice for all experiments. After the tests, the animals were euthanized using a CO₂ chamber, according to ethical parameters previously described.

Plasmas and venoms

For venom milking of the 13 *B. moojeni* snakes, the specimens were individually anesthetized using a CO₂ chamber. Venom samples were individually and manually collected, centrifuged at 1,700 x g for 15 min, lyophilized, and stored at -20° C until analyses. The *B. jararaca* venom pool, also obtained from the Laboratory of Herpetology of Instituto Butantan, which has been analyzed in a previous work [42], was used in some experiments for comparative purposes.

B. moojeni plasmas were obtained through blood collection from the same snakes in the presence of anticoagulant sodium citrate (3.8%) (9 volumes of plasma to 1 volume of anticoagulant) and centrifugation at 1,200 x g at room temperature for 15 min. Plasmas were stored at -20° C until use.

Antivenom

Antibothropic antivenom produced by hyperimmunization of horses with a pool of five *Bothrops* species venoms, namely, *B. alternatus* (12.5%), *B. jararaca* (50%), *B. jararacussu* (12.5%), *B. moojeni* (12.5%), and *B. neuwiedi* (12.5%) was provided by the Plasma Processing Section of Butantan Institute, SP, Brazil (Batch 0712240/B).

Compositional analyses of *B. moojeni* plasma and/or venom

Protein quantification. Protein concentration was assayed on individual plasmas and venoms according to the method described by Bradford [43] using the Bio-Rad Protein Assay reagent and bovine serum albumin (BSA) as standard. All samples were assayed in triplicate. Data were expressed as mean \pm SDM.

Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Venom and plasma samples were subjected to SDS-PAGE on 15 and 10% polyacrylamide gels, respectively, according to the method described by Laemmli [44]. Twenty micrograms of proteins were homogenized with sample buffer in the presence of 2-mercaptoethanol and applied to each lane. The polyacrylamide gels were stained using Coomassie Blue G250 according to the manufacturer's recommendations (GE Healthcare).

High performance liquid chromatography (HPLC). Five hundred micrograms of lyophilized individual venoms were dissolved in 200 μ L of 0.1% trifluoroacetic acid (TFA; solution A), centrifuged at 13,000 \times g for 15 minutes, and separated by Reversed phase high performance liquid chromatography (RP-HPLC) using a Teknokroma Europa Protein 300 C18 column (0.46 cm \times 25 cm, 5 mm particle size, 300 \AA pore size). Elution was conducted at 1 mL/min by applying a gradient towards solution B (95% acetonitrile containing 0.1% TFA) according to Gay et al. [40] with some modifications: 5% B for 5 min, 5–25% B for 10 min, 25–45% B for 60 min, 45–70% B for 10 min, 70–100% B for 10 min, and 100% B for 10 min. Protein profile was detected at 215 nm.

Identification of plasma protein bands from SDS-PAGE. Protein bands from SDS-PAGE (S2 Fig) were excised and *in-gel* trypsin digestion (using 10 ng/ μ L sequencing-grade trypsin in 50 mM ammonium bicarbonate) (Sigma) was performed according to Hanna et al. [45]. Tryptic digests were dried in a SpeedVac (GeneVac) and stored at -20°C prior to LC-MS/MS analyses. Mass spectrometry experiments of venom digests were performed on a Synapt G2 HDMS (Waters) mass spectrometer coupled to a nanoAcquity UPLC system (Waters). Each peptide mixture was loaded online for 5 min at a flow rate of 8 μ L/min of phase A (0.1% formic acid) using a Symmetry C18 trapping column (5 μ m particles, 180 μ m \times 20 mm length; Waters). The mixture of trapped peptides was subsequently separated by elution with a gradient of 7–65% of phase B (0.1% formic acid in acetonitrile) through a BEH 130 C18 column (1.7 μ m particles, 75 \times 150 mm; Waters) in 20 min at 275 nL/min. Data were acquired in the data-independent mode MS^E in the m/z range of 50–2000 and resolution mode.

Collision energies were alternated between 4 eV (low energy) and a ramp of 19–45 eV (high energy) for precursor ions (MS) and fragment ions (MS/MS), respectively. Each MS and MS/MS step last 1 s, resulting in duty-cycles of 2 s. The electrospray ionization (ESI) source was operated in positive mode with a capillary voltage of 3.1 kV, block temperature of 100°C , and cone voltage of 35 V. For lock mass correction, a [Glu1]-Fibrinopeptide B solution (500 fmol/mL in 50% acetonitrile, 0.1% formic acid; Peptide 2.0) was infused through the reference sprayer at 500 nL/min and sampled every 60 s. Venom samples were analyzed in technical triplicates. Mass spectrometry raw data were processed in ProteinLynx Global Server 3.0.3 (Waters) platform using a low energy signal threshold of 750 counts and an elevated energy signal threshold of 50 counts. Database searches were performed against Serpentes (taxid:

8570) sequences from UniprotKB/Swissprot (www.uniprot.org; 2,608 reviewed sequences, downloaded on March 1st, 2019). The spectral deconvolution process for the MS^E experiments is described by Silva et al. [46]. Briefly, the algorithm cluster peptide components by accurate mass and retention time (AMRT) in the parallel low energy (MS1) and high-energy (MS2) acquisitions. The low-energy precursor ions are associated with their corresponding high-energy fragment ions by the obtained chromatographic attributes. The following search parameters were used: automatic tolerances for precursor and fragment ions, carbamidomethylation of cysteine residues as fixed modification, oxidation of methionine, N-terminal acetylation, glutamine and asparagine deamidation as variable modifications, and trypsin digestion with up to two missed cleavage sites allowed. Protein identifications were considered with a minimum of one fragment ion per peptide, five fragment ions per protein, two peptides per protein, and a false discovery identification rate set to 1%, estimated by simultaneous search against a reversed database [47,48].

Shotgun proteomics. Venom samples of 100 µg were dissolved in 50 µL of 50 mM ammonium bicarbonate, followed by addition of 25 µL of 0.2% RapiGest SF (Waters), and incubation at 80°C for 15 min. Samples were reduced with 5 mM dithiothreitol at 60°C for 30 min and then alkylated in the dark with 10 mM iodoacetamide at room temperature for 30 min. Proteins were digested using trypsin (Promega) at a 1:400 (wt:wt) enzyme:protein ratio at 37°C overnight. Digestion was stopped by addition of 10 µL of 5% trifluoroacetic acid and incubation at 37°C for 90 min. Samples were filtrated through 0.22 µm Millex-GV filters (EMD Millipore) into glass vials. The final protein concentration was approximately 2 µg/µL. Mass spectrometry experiments of venom digests were performed on a Synapt G2 HDMS (Waters) mass spectrometer coupled to a nanoAcquity UPLC system (Waters). Approximately 5 µg of each peptide mixture was loaded online for 5 min at a flow rate of 8 µL/min of phase A (0.1% formic acid) using a Symmetry C18 trapping column (5 µm particles, 180 µm x 20 mm length; Waters). The mixture of trapped peptides was subsequently separated by elution with a gradient of 7–35% of phase B (0.1% formic acid in acetonitrile) through a BEH 130 C18 column (1.7 µm particles, 75 x 150 mm; Waters) in 90 min at 325 nL/min. Data were acquired in the data-independent mode HDMS^E with ion mobility separation in the m/z range of 50–2000 and resolution mode. Collision energies were alternated between 4 eV and a ramp of 22–55 eV for precursor ion and fragment ions, respectively, using scan times of 1.0 s. The ESI source was operated in positive mode with a capillary voltage of 3.1 kV, block temperature of 100°C, and cone voltage of 35 V. For lock mass correction, a [Glu1]-Fibrinopeptide B solution (500 fmol/mL in 50% acetonitrile, 0.1 formic acid; Peptide 2.0) was infused through the reference sprayer at 500 nL/min and sampled every 60 s. Venom samples were analyzed in technical triplicates. Mass spectrometry raw data were processed in ProteinLynx Global Server 3.0.3 (Waters) platform using a low energy threshold of 750 counts and an elevated energy threshold of 50 counts. Database searches were performed against Serpentes sequences from UniprotKB/Swissprot (www.uniprot.org; 2,608 reviewed sequences, downloaded on March 1st, 2019). The following search parameters were used: automatic tolerances for precursor and fragment ions, carbamidomethylation of cysteine residues as fixed modification, oxidation of methionine, N-terminal acetylation, glutamine and asparagine deamidation as variable modifications, and trypsin digestion with up to two missed cleavage sites allowed. Protein identifications were considered only peptides with a minimum of 2 fragment ions per peptide, 5 fragment ions per protein and at least 2 peptides for protein, and a false discovery identification rate set to 1%, estimated by simultaneous search against a reversed database [47]. Label-free quantification was performed in ISOQuant [49] considering the averaged intensities of the three most intense peptides of each identified protein [50]. Significance of the differentially abundant proteins between the groups (with fold change ≥ 1.5 or ≤ 0.67) was determined using unpaired Student's *t*-test

considering $p < 0.05$. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE [51] partner repository with the dataset identifier PXD012585

Functional analyses of *B. moojeni* plasma and/or venom

Western Blotting. The Western Blotting method [52] was used to verify the occurrence of protein binding between *B. moojeni* plasma and venom proteins. The proteins present in plasma, after SDS-PAGE separation, were transferred to a PVDF membrane (GE Healthcare) previously equilibrated in transfer buffer (25 mM Tris-base, 192 mM glycine, 20% ethanol) for 2 h, with a voltage of 20 V in a TE 77 PWR system (GE Healthcare). After transfer, the membrane was stained with Ponceau S to verify transfer efficiency (Ponceau 0.5% and acetic acid 1%) and destained with deionized water. After that, the membrane was cut to separate different specimen plasma lanes and then blocked with defatted milk (5%) containing 0.01% Tween 20 (incubation solution) and incubated overnight at 4°C. After three successive washes (5 min each) with washing solution (10 mM Tris, 150 mM NaCl, 0.01% Tween 20, pH 7.5), the membrane was incubated with the respective or non-self-venom (diluted 1:1,000) in incubation solution for 1 h at room temperature. The membrane was then incubated with antithrombotic serum (Instituto Butantan) (diluted 1:1,000) for 2 h at room temperature. Immune-recognized proteins were detected using peroxidase-labeled for anti-horse IgG (diluted 1:10,000) and then revealed by adding the chromogenic substrate (5 mg of 3,3'-diaminobenzidina tetrahydrochloride in 10 mL of imidazole buffer 0.1M, 125 μ L 0.2 M CoCl₂, and 3.4 μ L 30% H₂O₂). Negative controls (data not show) were made with a membrane of only the plasma transferred from the SDS-PAGE and other with only individual venom samples.

Caseinolytic activity. Venom proteolytic activity on casein was determined as described by Menezes et al. [20]. Briefly, 10 μ L of venom solution (1 mg/mL) and 500 μ L of a solution of 2% N,N-dimethylated casein (Sigma), both solubilized in same buffer, were added to 490 μ L of buffer (100 mM Tris-HCl, 10 mM CaCl₂, pH 8.8). The mixture was incubated for 30 min at 37°C. The reaction was stopped by adding 1 mL of 5% trichloroacetic acid (TCA). The sample was then incubated for 10 min in ice bath, centrifuged at 14,000 x g at 4°C for 15 min, and absorbance of the supernatants was performed in a plate reader (Epoch-Biotek) using a wavelength of A₂₈₀. Specific activity was expressed as units per minute per milligram of protein (U/min/mg).

Collagenolytic activity. Collagenolytic activity was determined as described by Vachova and Moravcova [53] and modified by Antunes et al. [54]. 6.25 μ g of venom were incubated with 50 μ L of 5 mg/mL azocoll (Sigma) solution, both resuspended in Tyrode buffer (137 mM NaCl, 2.7 mM KCl, 3.0 mM NaH₂PO₄, 10 mM HEPES, 5.6 mM dextrose, 1 mM MgCl₂, 2 mM CaCl₂, pH 7.4), in Thermo-shaker (Kasvi[®]) at 37°C and 1000 rpm for 1 h. The reaction was stopped by placing samples on ice. After centrifugation for 3 min at 5,000 x g, the absorbance of the supernatant (200 μ L) was measured at 540 nm using a SpectraMax i3 microplate reader (Molecular Devices). One unit of activity was defined as the amount of venom that causes an increase of 0.003 units of absorbance, and specific activity was expressed as U/min/mg of venom. All samples were assayed in triplicate. Data were expressed as mean \pm SDM.

Phospholipase A2 (PLA₂) activity. The method based on the substrate 4-nitro-3-octanoyloxy benzoic (NOBA) cleavage in the presence of phospholipase, releasing a chromogenic product that is measured at A₄₂₅ [55], was employed to measure the PLA₂ activity. Lyophilized venoms were diluted in 0.85% saline solution (1 mg/mL). In 96-well microplates (Sarstedt), 20 μ L of venom samples were added to 20 μ L of deionized water, 200 μ L of 10 mM CaCl₂, 10 mM Tris buffer and 100 mM NaCl pH 8.0, and 20 μ L of 3 mM NOBA (in acetonitrile). Next,

the plate was incubated at 37°C for 20 min, followed by measuring of the A_{425} . An increase of 0.1 A_{425} unit is equivalent to the release of 25.8 nmoles of chromophore. PLA_2 activity was expressed as nmoles of chromophore released per minute of incubation per mg of protein (nmoles/min/mg).

L-Amino-acid oxidase (LAAO) activity. LAAO activity of venoms was determined using the method based on the amount of hydrogen peroxide released by the reaction between the LAAOs present in the venom and the reactive mixture [56]. Lyophilized venoms were diluted in 0.85% saline solution to a concentration of 0.5 mg/mL. Ten microliters of sample were incubated with 90 μ L of reactive mixture (composed of 50 mM Tris-HCl, pH 8.0, 250 mM L-methionine, 2 mM o-phenyldiamine (OPD), and horseradish peroxidase 0.8 U/mg) in microplates (Sarsted) at 37°C for 1 h. The reaction was then stopped with 50 μ L of 2 M H_2SO_4 and read at A_{492} in a plate reader (Epoch–Biotek). Determination of the LAAO activity was performed using a standard curve of hydrogen peroxide. Results were expressed as μ M of H_2O_2 produced/min/mg of venom (nM/mg/min).

Coagulant activity. Minimum Coagulant Dose (MDC) was defined as the smallest amount of venom that clotted a standardized citrated plasma or fibrinogen solution in 60 seconds at 37°C [57].

MCD was determined in samples of citrated bovine plasma (MCD-P) and bovine fibrinogen solution (2 mg/mL) (MCD-F), as described by Theakston and Reid [57]. Venoms were diluted in 0.85% saline solution in concentrations ranging from 1.95 to 1,000 μ g/mL. Clotting time was obtained by adding 100 μ L of each venom dilution to 200 μ L of plasma or fibrinogen, maintained at 37°C. Coagulation time was recorded immediately after addition of the venom dilution to the coagulometer (Drake).

Hemorrhagic activity. Hemorrhagic activity was measured as previously described [58] and modified by Gutiérrez et. al. [59]. Five groups of five male Swiss mice weighing 18–22 g were injected intradermally in the abdominal region with different doses of venom (2.5, 5, 10, 20 and 30 μ g/mL) in volumes of 100 μ L. After 2 hours of inoculation, mice were euthanized using a CO_2 chamber. The skin of the ventral region was removed and fixed on a glass plate. The hemorrhagic area was transferred to a white paper sheet, subsequently digitized, and measured using the ImageJ software. The minimum hemorrhagic dose (MHD) was defined as the amount of venom that produces a 10 mm diameter hemorrhagic halo.

Lethal dose. Median lethal dose (LD_{50}) was defined as the dose responsible for the death of 50% of the population analyzed [60]. Different doses of venom (44.4, 66.6, 100, 150 and 225 μ g/mL) were resuspended in 500 μ L of sterile 0.9% saline solution and injected intraperitoneally in the male Swiss mice (18–22 g). Five animals were used for each venom dose (55 animals– 25 per group, including one control group). Deaths were registered during a 48 h period (4h interval, approximately), and the LD_{50} was estimated by Probit analyses [61]. Remaining mice were euthanized utilizing previously described protocol.

Statistical analysis

Data were expressed with median and \pm standard deviation (SD). Results were analyzed with one-way ANOVA, with Tukey as a posteriori test and values of $p < 0.05$ was considered significant.

Results and discussion

Compositional and functional analyses of *B. moojeni* plasma and venom

In this work, we used an unbalanced sex distribution of individuals (only three males to ten females) since we were bounded to the individuals available for this study in our laboratory. At




Fig 2. Protein profile of *B. moojeni* plasma samples. *B. moojeni* plasma samples (20 μ g) were individually analyzed by SDS-PAGE (10%) under reducing conditions. Gels were stained with Coomassie Blue G250. Lanes correspond to individual plasmas from specimens Bm1 to Bm13.

<https://doi.org/10.1371/journal.pone.0222206.g002>

that time, we have other male individuals from the same region (Araraquara - SP) and that would not increase our range of individuals from different regions, as we had with the female distribution. We also did not use any juvenile individuals in our analysis, since all the cases of cross envenomation observed by our group was among adult individuals only, during mate season. From this statement, our results will now be discussed below.

The protein profile of individual plasmas was analyzed by 10% SDS-PAGE under reducing condition. Fig 2 shows the electrophoretic profile of *B. moojeni* snake plasmas, numbered from 1 to 13.

Patterns of plasma proteins showed similarity between all samples, with slight differences in the intensity of few bands, especially in bands with ~30 kDa and ~37 kDa. Although no exclusive bands were visually identified, it was possible to notice that some points, such as the region immediately below the 50 kDa in individuals 6 and 11, displayed a well-defined band that barely appeared in others. Between 50–75 kDa, three intense bands and bands with different concentration were observed in all individuals, showing some degree of variability. Snake plasma composition of the *Bothrops* genus includes, but it is not limited to, gamma-type PLA₂ inhibitors (at the 20~30 kDa range), transferrins, antihemorrhagic factor, and albumin (50~150 kDa) [18], a myotoxin inhibitor that has already been described with 25 kDa [41] and B_j46a, which is a glycoprotein that inhibits metalloproteinases and has been previously found in *B. jararaca* [62].

Protein bands were assigned to the major protein families according to previously studies. The profile of individual venom samples was analyzed by 15% SDS-PAGE under reducing condition. As shown in Fig 3, the electrophoretic profile of *B. moojeni* snake venoms showed a remarkable intraspecific variation between specimens. First, individual 3 showed a profile distinct from the others, with lack of a band in the 20–25 kDa region and higher variability in the 25–37 kDa range of the gel. Some individuals showed similar SDS-PAGE profile, as in the case




Fig 3. Protein profile of *B. moojeni* venom samples. *B. moojeni* venom samples (20 µg) were individually analyzed by SDS-PAGE (15%) under reducing conditions. Gels were stained with Coomassie Blue G250. Lanes correspond to individual plasmas from specimens Bm1 to Bm13.

<https://doi.org/10.1371/journal.pone.0222206.g003>

of individuals 9, 10, 11, and 13, all originally from the same region (Table 1). These four specimens were brought to Instituto Butantan in 2013, except the individual 10, which arrived a year earlier. Therefore, it is interesting to point out that, even with different captivity periods, these four individuals from the same geographic region still presented similar protein profiles. All individuals showed a band with ~100–150 kDa, except individual 1. This region corresponds to phosphodiesterases (PDE) and/or prothrombin activator subunits [63,64]. The region between ~50–75 kDa presented a major protein band in all individuals. This band corresponds to snake venom metalloproteinases class P-III (SVMP-III), one of the main groups of toxins of genus *Bothrops* venoms [63,65,66]. It was also possible to note that this area presents two bands instead of only one in individuals 4, 6, and 13. A band with 37 kDa was observed in all venoms, except in those of individuals 2 and 7. The venoms showed a variable band composition in the range of 25–37 kDa, displaying at least five protein bands. In contrast, individual 7 presented less intense bands in this region. Specifically, individuals 2, 7, 8, and 12 lack a band in the 25 kDa region, whereas individual 13 presented the most intense 25 kDa band. The main components assigned to molecular range between 25–37 kDa are snake venom serine proteases (SVSP) and snake venom metalloproteinases class P-I and P-II (SVMP-I and SVMP-II) [65]. The most intense band in all samples was located between 20 and 25 kDa. Surprisingly, individual 3 did not present this band, whereas individuals 2, 5, and 6 markedly showed two bands. Finally, the region between 10 and 15 kDa, associated with PLAs [67], showed a slight variation between the samples. All individuals exhibited two intense bands in this region, except individuals 3 and 7, which showed only one intense band. The profile of individual 7 is different from that of individual 12, although both came from the same region, but in different years (seven in 2008 and 12 in 2005). These results show the high variability in venom composition between individuals of this species, as well as compared with other species




Fig 4. Interaction between *B. moojeni* plasma and venom proteins evaluated by Western blotting. *B. moojeni* plasma proteins (20 μ g of protein) were fractionated by SDS-PAGE (10%, under reducing conditions), electrotransferred onto PVDF membranes, and incubated with the respective venom, prior to the incubation step with antithrombotic serum.

<https://doi.org/10.1371/journal.pone.0222206.g004>

previously mentioned by other authors [16,37,68]. In fact, snake venoms are the result of a series of adaptations in their composition in order to make the best protein mixture to both type of prey and the environment in which snakes are inserted [69]. In addition, the quantitative and qualitative composition of the venoms are associated with several factors such as habitats, gender, age, and nutrition [37,70–72], and cannot be directly related to one single factor.

As many different profiles were found, we decided to subject all individual venom samples to the WB technique so that the interaction between plasmatic proteins and their respective venom could be analyzed. As shown in Fig 4, there are peculiar binding regions in the range of 20–30 kDa of plasma proteins, indicating interaction between plasma and venom proteins in individuals 2, 6, 7, 8, 9, and 13.

In order to analyze whether there was cross-reactivity between plasma and venom proteins from different specimens of *B. moojeni*, another set of WB was performed. Three individuals were selected for these experiments: two venom samples from individuals that presented that interaction (specimens Bm2 and Bm8) and one sample from an individual that did not show the interaction (specimen Bm4). Results revealed that the plasma sample from the specimen that previously did not present a recognition area in the 20–30 kDa region, when incubated with venom from a specimen (Bm2 or Bm8) that showed the previously immune interaction, also exhibited the recognition reaction in this region (Fig 5). This finding suggests that the differences on the recognition pattern observed by WB are associated with venom composition, considering that the venom of an individual that interacts with its own plasma is also able to interact with plasma from other individuals.

The plasma proteins with ~25 kDa involved in the recognition of venom proteins were identified by mass spectrometry after in gel trypsin digestion. Results (S2 Fig and S1 Table) showed that these protein bands correspond mainly to PLA₂ inhibitors, as previously described in *B. moojeni* plasma [41]. In addition, the anti-hemorrhagic factor BJ46a (FTE46_BOTJA), a molecule originally described in *B. jararaca* plasma [62], was also identified.




Fig 5. Cross-reactivity between plasmas and venoms from different specimens of *B. moojeni*. *B. moojeni* plasma proteins from specimens Bm2, Bm4, and Bm8 (20 μ g of protein) were fractionated by SDS-PAGE (10%, under reducing conditions), electrotransferred onto PVDF membranes, and incubated with the non-self venom prior to the incubation step with antiothropic serum. The first number below the membrane strips corresponds to the plasma specimen number and the second number corresponds to the venom specimen number.

<https://doi.org/10.1371/journal.pone.0222206.g005>

RP-HPLC

The protein profiles of all thirteen individuals were evaluated by RP-HPLC in a C18 column. In general, results showed a typical bothropic chromatographic venom profile (Fig 6), but also evidenced differences regarding peak intensity in some samples. Using a previous report as a proteomic reference [73], the peaks eluted before 25 min are mainly composed of disintegrins, K-49 PLA₂ are eluted after ~45 min mark, SVSP, SVMP-I, D-49 PLA₂, and LAAO are grouped in different peaks between 50–75 min, and SVMP-III predominating after the 75 min mark. A difference in the K-49 PLA₂ region was observed when the individual HPLC profiles were




Fig 6. Elution profiles of *B. moojeni* venom proteins by RP-HPLC. Samples of 500 µg of lyophilized venoms from specimens Bm1 to Bm13 were dissolved in 0.1% trifluoroacetic acid (TFA; solution A) and subjected to RP-HPLC in a C18 column. Elution was conducted at 1 mL/min by applying a gradient towards solution B (95% acetonitrile containing 0.1% TFA) as follows: 5% B for 5 min, 5–25% B for 10 min, 25–45% B for 60 min, 45–70% B for 10 min, 70–100% B for 10 min, and 100% B for 10 min. Absorbance was measured at 215 nm.

<https://doi.org/10.1371/journal.pone.0222206.g006>

compared. This species seemed to present two profiles in this area: one showed a single peak (individuals 1, 2, 4, 12, and 13) and the other presented two distinct peaks (individuals 3, 5, 6, 7, 8, 9, 10, and 11). Individual 13 presented a small peak in this area. A variable region was also observed around 60 min, which comprises several major protein families. The SVMP region showed variable profiles between individuals as well. The individuals presented between one and four peaks in this area. Results also showed that even the individuals of the same sex or from the same region exhibit variable chromatographic profiles, with quantitative and qualitative differences. However, this higher individual variability was expected because the first analyses and results of this study corroborated those of other studies [74–76]. Since it was in our best interest to identify the differences found previously, we decided for two individuals that represented, so to speak, the two different ‘groups’ that we identify with the WB test. With that in mind, the individuals Bm2 and Bm4 were selected to be used on a more thorough analysis. For the *in vivo* assays and to be analyzed by Quadrupole time-of-flight—Nanoflow electrospray-ionization (QTOF-nanoESI). With that in mind, we will discuss all the following results focusing specifically on these two individuals.

Shotgun proteomics

Protein composition of Bm2 and Bm4 was determined by quantitative shotgun proteomics. In the search engine ProteinLynx Global Server (PLGS), we have the option to set mass error tolerances in automatic mode or to define a fixed mass error. In the automatic mode, PLGS calculates the appropriate tolerances based on the error distribution of the PSM identifications. We see from our data that most PSM are within the 10 ppm mass window and none outside the 40 ppm window. The results (S1 Table) showed identification of one exclusive protein in the venom of Bm2 and nine in Bm4. A basic PLA₂ Lys-49 (Accession code: Q9I834) was the only exclusive protein found in the Bm2 venom. This protein lacks enzymatic activity (due to the presence of a lysine at position 49) but display myotoxicity and edema-inducing activity [77]. Bm4 also have an exclusive PLA₂ with the same characteristics (Q9PVE3), and other one that shows enzymatic activity (P0C8M1). Besides that, this individual also presented three metalloproteases; one with weak hemorrhagic activity (P83512), one PII type (O57413) and one PIII type (Q9DGB9). Other three serineproteases were also found in its composition: one thrombin-like that does not coagulate human plasma (P81176), other thrombin-like with fibrinolytic activity *in vitro* and defibrinogenating *in vivo* (K4LLQ2) and the last one that plays a role in the hemostasis system on the prey (Q5W960). Together, these two individuals share a total of 60 common proteins. Regarding the families of those common proteins, these compounds belong to PLA₂, C-type lectin, LAAOs, metalloproteinases, serine proteases, CRISPS, Glutamyl-peptide cyclotransferases (GPC), and neural growth factors. Fig 7 shows a quantitative distribution of the compounds present in both individuals. It could be possible that the exclusive PLA₂ found in Bm2 is the one that reacts with the plasma samples during the Western blotting assay, since that plasma region is composed mostly by gamma-PLI inhibitor (S2 Table).

The abundant amount of serine proteases (14.41% in Bm2 and 17.94% in Bm4) and type III metalloproteinases (20.24% in Bm2 and 25.53% in Bm4) was expected considering that *B. moojeni* is well known for its higher proteolytic and hemorrhagic activities [78]. That may be the cause of edema and generalized hemorrhage previously reported in the *B. moojeni* autopsy records of individuals in our laboratory. There have been reported some cases of death suggestive of envenomation by bites by other individuals during the mating season, when these animals were grouped to copulate (in captivity). The autopsy records described anomalies registered as “hemorrhage regions in the ventral and distal areas”, even when the bite had




Fig 7. Overall composition of *B. moojeni* snake venom. Individuals Bm2 and Bm4, according to protein families, expressed as percentages. (PI-, PII- and PIII-SVMP) snake venom metalloproteinase of PI, PII and PIII class, respectively; (SVSP) snake venom serine protease; (D49/K49 PLA₂) phospholipase A₂ D49 and 49, respectively; (CRISP) Cysteine-rich secretory protein; (5'ND) 5'Nucleotidase; (PLB) phospholipase B; (GPC) Glutamyl-peptide cyclotransferase; (CTL) C-type lectin; (PDE) phosphodiesterase; (LAAO) L-amino acid oxidase; (VNGF) venom nerve growth factor; (PrAct) prothrombin activator; (PlasmAct) plasminogen activator.

<https://doi.org/10.1371/journal.pone.0222206.g007>

occurred in a distant region, such as the tail or head of the animal (S1 Fig). The bothropic venom is well known for its ability to cause local tissue damage and other proteolytic disturbances such as hemorrhage and/or coagulation. It is worth noting that snakes, along with some of their prey and predators, have “protecting factors”, known as inhibitors, which protect them from the effects of the many different toxic proteins present in their composition. These intriguing cases of death by envenomation can be associated with the high variability that these individuals present in their venom composition, as well as with the analyses of the specific activities that will be described ahead.

Functional analyses of *B. moojeni* venom

Caseinolytic activity. Venom proteolytic activity using casein as substrate showed a diverse profile between all 13 individuals (Fig 8A). The highest activity was from individual Bm2, with 702.22 ± 6.94 U/min/mg, whereas the lowest one was from individual Bm11, with 202.22 ± 1.92 U/min/mg. In addition, individual Bm2 is statistically different from all other ones, while Bm4 did not showed statistical difference with individuals Bm3, 10 and 12.

Collagenolytic activity. Using collagen to evaluate the proteolytic activity, a pattern different from that described using casein as substrate was observed. Interestingly, the highest caseinolytic activities were found in individuals whose venom showed plasma interaction (Fig 8B). Statistically, individual Bm2 showed the same results from caseinolytic activity, while Bm4 differed from the samples Bm6, 7, 8 and Bj. In addition, these results are in agreement with those obtained in the chromatography profiles: when an individual showed a distinct second and/or third peak after the 75 min mark, its proteolytic activity presented a result higher than those of other individuals, suggesting the presence of a collagen-specific protease in this fraction. Curiously, our MS results showed a different pattern between individuals Bm2 and Bm4. While the second one presented a higher total concentration of proteases, its proteolytic









Fig 8. Enzymatic activities of *B. moojeni* individual venoms. Results of biological characterization assays of all 13 *B. moojeni* and one *B. jararaca* individuals. Collagenolytic activity (A); caseinolytic activity (B); PLA₂ activity (C); LAAO activity (D); MCD-Plasma activity (E); MCD-Fibrinogen activity (F).

<https://doi.org/10.1371/journal.pone.0222206.g008>

results were lower than the Bm2. Roodt et al. previously reported that *B. moojeni* presents higher proteolytic activity compared with that of other snakes from the *Bothrops* genus [79]. In this study, *B. jararaca* venom, used as control, showed a caseinolytic activity of 462.22 U/min/mg, approximately 35% lower than the value of 703.99 U/min/mg obtained from the individual with the highest caseinolytic activity that positively reacted with plasma, as demonstrated by the WB test. Curiously, in the collagenolytic assay, different pattern was observed, in which the *B. jararaca* sample showed the highest collagenolytic activity among all samples tested. These results demonstrate that, differently from *B. moojeni* proteases, *B. jararaca* proteases present higher specificity to collagen than to casein.

PLA₂ activity. Concerning the PLA₂ activity of individual venoms, different results were obtained between the samples, ranging from 11.18 ± 1.97 to 27.09 ± 9.14 nmols/min/mg (Fig 8C). Statistics showed no significant differences amongst all samples, with the exception of Bm6 (different from Bm8) and Bm8 (different from Bm6, 12 and 13).

LAAO activity. LAAO activity also showed high individual variations. Statistics confirm this affirmation, with all individuals showing differences between them all (p < 0.05). The values obtained for this enzymatic activity ranged from 72.73 ± 2.02 to 262.98 ± 2.86 nM/μg/min (Fig 8D). Mass spectrometry showed a different result, with individual Bm4 having a higher activity (against Bm2), despite its lower LAAO abundance (17.68%) in comparison with Bm2 (23.72%).

Campos and colleagues [80] also compared the PLA₂ and LAAO activities between the venoms of *B. moojeni* and those of other snakes of the *Bothrops* genus and concluded that the venom of the first presents higher activities than those of the latter. These data support the present study, in which more than 50% of the *B. moojeni* individuals showed increased PLA₂ activity compared with that of *B. jararaca*. Regarding the LAAO activity, all *B. moojeni* individuals presented higher activity than *B. jararaca* individuals, as depicted in Fig 8. While mass spectrometry results confirm the PLA₂ results, in which the individual Bm4 showed a higher specific activity when compared to the Bm2 individual, the LAAO results showed an inverse result when comparing the same two individuals (Fig 7). It is known that the LAAOs act as adjuvants in envenoming, in which the H₂O₂ released causes a cytotoxic effect by increasing the action of other proteins present in the venom. They are responsible for some different biological activities, including cytotoxicity, tissue necrosis, apoptosis induction, and platelet aggregation inhibition, causing innumerable hemostatic disorders. All these activities are closely related to the cases of bleeding, important in the envenoming process [81–84]. PLA₂ activities, which act in the lipid bilayer deconstructing the cell membrane, also have activities such as neurotoxic effects, myotoxicity, inhibition of platelet aggregation, edema, hemolysis, anticoagulation, convulsion, and hypotension [85–87].

Minimum coagulant dose. Both substrates used in this experiment (plasma and fibrinogen) showed high individual variability between all samples (Fig 8E and 8F). Regarding coagulation on plasma, individual Bm6 presented the lowest MCD (3.9 ± 0.10 μg/mL) and individual Bm4 showed the highest MCD (125.99 ± 11.72 μg/mL) on the same substrate. With respect to fibrinogen, individuals Bm2 and Bm5 presented the highest and lowest MCD, 44.85 ± 6.97 and 4.14 ± 1.55 μg/mL, respectively. In addition, individual Bm2, which was used alongside with individual Bm4 in the *in vivo* assays, showed a low MCD-P (5.57 ± 0.32) and a high MCD-F (44.85 ± 6.97). Statistically, individuals Bm10, 12 and 13 showed differences only with *B. jararaca*. Both individuals analyzed by mass spectrometry have a similar abundance of SVSP (Bm2

18.25%; Bm4 19.60%) in its composition. It is important to point out that the plasma used in this assay was not recalcified to match its original physiological state. This lack of recalcification may have influenced the relative potency of those venoms, altering its original coagulation times, since it is known by recent studies that snakes from the *Bothrops* genus are highly calcium dependent when it comes to coagulation properties [88]. There might be some variation in calcium dependence state among different individuals, but we could not observe that in this study. So, for future references, our group will perform coagulations assays with recalcified plasma only. Therefore, this coagulation data shall be compared only to results from other works that also did not recalcified their substrates as well.

The two individuals analyzed showed an inversely proportional in their coagulation doses on different substrates, with Bm2 having a very low dose for plasma and a higher one for fibrinogen, while Bm4 having a higher dose for plasma and a lower one for fibrinogen. These differences can be explained by the fact that, while using plasma from any source, the venom toxins work in synergy to act in different steps of the blood coagulation cascade. On the other hand, using fibrinogen, the toxins act only in the last step of the coagulation mechanism, which involves consumption of the fibrinogen available in the circulation and formation of fibrin clot by action of the thrombin-like enzymes [89]. Therefore, we could assume that some individuals have proteases with thrombin-like characteristics, while others act in other points of the coagulation cascade.

For the next assays, we decided to use only the Bm2 and Bm4 individuals, the same ones used in the QTOF-nanoESI, so we could focus at the individual variability. If instead of that we decided to work with a pool of two pre-defined groups, these informations could be lost. Moreover, since we here prioritize to use the least amount of live animal for *in vivo* assays, test the LD₅₀ and MHD of all of our thirteen individuals would be impracticable.

Minimum hemorrhagic dose. The hemorrhagic activity of two individual venoms, Bm2 and Bm4, was evaluated by determination of MHD. Interestingly, Bm2 venom showed a MHD of $3.21 \pm 0.63 \mu\text{g}$, whereas Bm4 venom presented a MHD approximately 52% lower ($1.55 \pm 0.35 \mu\text{g}$). Fig 9 depicts the hemorrhagic halo induced by injection of 5 μg of venom.

Lethal dose₅₀. The median lethal dose was determined using the same two venom samples used for determination of MHD, Bm2 and Bm4. During the experiment, 12 individuals from group Bm2 and 11 from Bm4 died. Both venoms showed comparable LD₅₀ values (105 and 113 $\mu\text{g}/\text{animal}$, respectively), with no significant differences considering the lower and upper confidence limits of 95% (Fig 10).

LD₅₀ is a standardize assay utilized to ensure the quality of the material during the preparation of venom batches utilized to produce the anti-venom serum [90] and is widely utilized in works that compare and characterize snake venoms, both from same and different species [42,91,92]. Comparison of LD₅₀ and MHD between the Bm2 and Bm4 individuals indicated that venom with lower hemorrhagic dose (Bm4) has a tendency to a higher lethal dose. In contrast, venom with a tendency to a lower lethal dose presents increased hemorrhagic dose (Bm2). Even if no significant difference is found in the LD₅₀, there is a tendency for this correlation, which has been previously documented. In 2012, Massey [16] conducted a study addressing the variability and severity of envenoming by snakes of the species *Crotalus scutulatus scutulatus* collected in counties in the states of Arizona and New Mexico, USA. The authors analyzed venoms of rattlesnakes from different locations and found that venom lethality decreased from central to southeastern regions. In addition, with this shift, the content of SVMP in those venoms also changed, with individuals with higher concentration of this compound showing lower lethality and individuals with lower contents showing a higher lethality.

It is also curious to note that both individuals in the present study showed an inverse result for the *in vitro* coagulation with fibrinogen and plasma. Individual Bm2, which was less




Fig 9. Hemorrhagic activity of two individual venoms of *B. moojeni* snakes. The hemorrhagic halos were the result of the intradermal injection of 5 µg of *B. moojeni* venom belonging to specimens Bm2 (A) and Bm4 (B).

<https://doi.org/10.1371/journal.pone.0222206.g009>

hemorrhagic *in vivo*, presented faster coagulation time. Moreover, individual Bm4 showed higher hemorrhagic activity and poor coagulation capacity with plasma. This phenomenon can be explained by the multiple interactions and synergy that venom toxins have in animals during *in vivo* assays that cannot be fully reproduced *in vitro*. In addition to the consumption of fibrinogen in the organism by thrombin-like venom enzymes, they also cause bleeding in the injured individual.

Considering the results obtained by mass spectrometry, it can be observed that both venoms had a similar LD₅₀ doses, but distinct DMH results. The venom that showed a slightly effective LD₅₀, Bm2, had a lower relative abundance of SVMP compared with the Bm4 venom.




Fig 10. Lethal dose (LD₅₀) of two individual venoms of *B. moojeni* snakes. The LD₅₀ was determined by the intraperitoneal injection of different doses of *B. moojeni* venom belonging to the Bm2 and Bm4 individuals. Median lethal dose (LD₅₀) is defined as the dose responsible for the death of 50% of the population analyzed.

<https://doi.org/10.1371/journal.pone.0222206.g010>

Furthermore, as SVMP is closely related to hemostatic disorders such as bleeding, venoms with a higher concentration of these proteins present a more potent hemorrhagic activity. The variation in the properties of hemorrhagic and lethal activities of venoms found in *B. moojeni* has been confirmed by other studies [6,78,93], and it occurs within other snake genera, and even in other snakes of the *Bothrops* genus [94]. *B. jararaca*, for example, also presents this variation between venoms of adult and juvenile individuals [95]. This change is due to the hemorrhagic effect caused by these venoms—a metalloproteinase P-III type characteristic, which is more abundant in these individuals in their adulthood. SVMP content variation was also observed in this study, in which a higher amount of SVMP was found in the venom of Bm4, thus making it more hemorrhagic than Bm2.

Concluding remarks

Unveiling snake venom profiles and their biological activities contributes to the elucidation of their complex envenomation mechanism and assists with future research. This study showed individual variability between the venoms of *B. moojeni* snake specimens. Moreover, these findings reinforce the diversity of venom phenotypes that can occur intraspecifically in many snake genera. It is also important to emphasize that putting all results together can contribute for the better understanding of the variability that has been proved to exist in *B. moojeni* and many other species. These studies also work for a greater good, when this type of analyses can contribute to other studies in the venomics and proteomics area, assisting with elucidating some of current proteomic questions. Therefore, it is in our best interest to contribute to the scientific development of this area, as a community, which tends to grow over time.

Supporting information

S1 Raw Images. Original images used in this work without any digital correction.
(PDF)

S1 Fig. Necropsy records of seven individuals of *B. moojeni* that showed signs of envenomation after being bitten by other individual of this species. Highlighted sessions of these files show a detailed analyses of different individuals with different symptoms.

- 1 –Two punctures in the right cranial region;
- 2 –Presence of blood in both the trachea and cranial region of the lungs;
- 3 –Thickened pericardium and hemorrhage in the aorta region.
- 4 –Macroscopic: hemorrhage;
- 5 –Blood vessels engorged and general hypovolemia in the byte region (cranial and 1/3 medium);
- 6 –Congested esophagus around the byte site;
- 7 –Congested testicles. Left testicle atrophied;
- 8 –Presence of blood cloth and hemorrhage in the 1/3 medial region. Reddish musculature around the byte site;
- 9 –Thickened pericardium with hemorrhage through the aorta;
- 10 –Congested testicles;
- 10 –Congested testicle;
- 11 –Blood vessels engorged at the superior region;
- 12 –Congested lungs. Hemorrhage at the cranial portion of the lungs;
- 13 –Engorged blood vessels at the byte site. Hypovolemia;
- 14 –Congested testicles;
- 15 –Engorged blood vessels at the medium region of the body (possible site of the byte);

16 –Yellowish liver. Presence of blood cloths in the caudal region;

17 –Congested testicles.

(TIF)

S2 Fig. SDS-Page scan of the protein bands excised and submitted to *in-gel* trypsin digestion. Samples from Bm1 to Bm7 belongs to *B. moojeni* plasma sample, while Bj8 to Bj13 it is from *B. jararaca*.

(PDF)

S1 Table. Proteins identified in individual venom from *B. moojeni* snakes individuals Bm2 and Bm4. Quantitative data were obtained through label-free quantification by high resolution LC-MS/MS considering the averaged intensities of the three most intense peptides of each identified protein.

(XLSX)

S2 Table. List of all plasma protein from *B. moojeni* identified by mass spectrometry, listed by: sample number, protein accession code and toxin class. Quantitative data were obtained through label-free quantification by high resolution LC-MS. Sample numbers can be verified in [S2 Fig](#).

(XLSX)

Author Contributions

Conceptualization: Weslei da Silva Aguiar, Kathleen Fernandes Grego, Karen de Moraes-Zani, Anita Mitico Tanaka-Azevedo.

Data curation: Weslei da Silva Aguiar, Nathália da Costa Galizio, Caroline Serino-Silva, Sávio Stefanini Sant’Anna, Kathleen Fernandes Grego, Alexandre Keiji Tashima, Erika Sayuri Nishiduka, Karen de Moraes-Zani, Anita Mitico Tanaka-Azevedo.

Formal analysis: Weslei da Silva Aguiar, Nathália da Costa Galizio, Caroline Serino-Silva, Alexandre Keiji Tashima, Erika Sayuri Nishiduka, Karen de Moraes-Zani, Anita Mitico Tanaka-Azevedo.

Funding acquisition: Karen de Moraes-Zani, Anita Mitico Tanaka-Azevedo.

Investigation: Weslei da Silva Aguiar, Nathália da Costa Galizio, Alexandre Keiji Tashima, Karen de Moraes-Zani, Anita Mitico Tanaka-Azevedo.

Methodology: Weslei da Silva Aguiar, Nathália da Costa Galizio, Caroline Serino-Silva, Alexandre Keiji Tashima, Karen de Moraes-Zani, Anita Mitico Tanaka-Azevedo.

Project administration: Weslei da Silva Aguiar, Karen de Moraes-Zani, Anita Mitico Tanaka-Azevedo.

Resources: Karen de Moraes-Zani, Anita Mitico Tanaka-Azevedo.

Software: Weslei da Silva Aguiar, Nathália da Costa Galizio, Caroline Serino-Silva, Alexandre Keiji Tashima, Erika Sayuri Nishiduka, Karen de Moraes-Zani.

Supervision: Karen de Moraes-Zani, Anita Mitico Tanaka-Azevedo.

Validation: Weslei da Silva Aguiar, Kathleen Fernandes Grego, Alexandre Keiji Tashima, Erika Sayuri Nishiduka, Karen de Moraes-Zani, Anita Mitico Tanaka-Azevedo.

Visualization: Weslei da Silva Aguiar, Alexandre Keiji Tashima, Karen de Moraes-Zani, Anita Mitico Tanaka-Azevedo.

Writing – original draft: Wesley da Silva Aguiar, Karen de Morais-Zani, Anita Mitico Tanaka-Azevedo.

Writing – review & editing: Wesley da Silva Aguiar, Nathália da Costa Galizio, Alexandre Keiji Tashima, Karen de Morais-Zani, Anita Mitico Tanaka-Azevedo.

References

1. Kellaway CH. The Immunity of Australian Snakes to Their Own Venoms. Vol. 2, The Medical Journal of Australia. 1931. p. 35–52.
2. Mackessy SP. Fractionation of red diamond rattlesnake (*Crotalus ruber ruber*) venom: protease, phosphodiesterase, L-amino acid oxidase activities and effects of metal ions and inhibitors on protease activity. *Toxicon*. 1985; 23(2):337–40. PMID: [2992122](#)
3. Noguchi H. Natural immunity of certain animals from snake venom. In: Snake Venom. ed. Washington D. C.: Carnegie Institute; 1909. p. 268.
4. White J, Meier J. Handbook of clinical toxicology of animal venoms and poisons. Vol. 236. CRC Press; 1995.
5. Bordon KCF, Wiesel GA, Cabral H, Arantes EC, Bordonein-L, a new L-amino acid oxidase from *Crotalus durissus terrificus* snake venom: isolation, preliminary characterization and enzyme stability. *J Venom Anim Toxins Incl Trop Dis*. 2015; 21:0.
6. Mamede CCN, de Sousa BB, da Cunha Pereira DF, Matias MS, de Queiroz MR, de Morais NCG, et al. Comparative analysis of local effects caused by *Bothrops alternatus* and *Bothrops moojeni* snake venoms: enzymatic contributions and inflammatory modulations. *Toxicon*. 2016; 117:37–45. <https://doi.org/10.1016/j.toxicon.2016.03.006> PMID: [26975252](#)
7. Marcussi S, Stábéli RG, Santos-Filho NA, Menaldo DL, Pereira LLS, Zuliani JP, et al. Genotoxic effect of *Bothrops* snake venoms and isolated toxins on human lymphocyte DNA. *Toxicon*. 2013; 65:9–14. <https://doi.org/10.1016/j.toxicon.2012.12.020> PMID: [23333649](#)
8. Menez A. Perspectives in molecular toxinology. John Wiley & Sons; 2002.
9. Ribeiro de Queiroz M, Mamede CCN, de Morais NCG, Cortes Fonseca K, Barbosa de Sousa B, Migliorini TM, et al. Purification and characterization of BmooAi: a new toxin from *Bothrops moojeni* snake venom that inhibits platelet aggregation. *Biomed Res Int*. 2014;2014.
10. Fox JW, Serrano SMT. Structural considerations of the snake venom metalloproteinases, key members of the M12 repolysin family of metalloproteinases. *Toxicon*. 2005; 45(8):969–85. PMID: [15922769](#)
11. Fry BG. From genome to “venome”: molecular origin and evolution of the snake venom proteome inferred from phylogenetic analysis of toxin sequences and related body proteins. *Genome Res* [Internet]. 2005 Mar [cited 2014 Dec 1]; 15(3):403–20. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=551567&tool=pmcentrez&rendertype=abstract> <https://doi.org/10.1101/gr.3228405> PMID: [15741511](#)
12. Ohno M, Menez R, Ogawa T, Danse JM, Shimohigashi Y, Fromen C, et al. Molecular Evolution of Snake Toxins: Is the Functional Diversify of Snake Toxins Associated with a Mechanism of Accelerated Evolution? *Prog Nucleic Acid Res Mol Biol*. 1997; 59:307–64.
13. Nobuhisa I, Inamasu S, Nakai M, I AT, Mimori T, Ogawa T, et al. Characterization and evolution of a gene encoding a *Trimeresurus fozoviridis* serum protein that inhibits basic phospholipase A, isozymes in the snake 's venom. *Eur J Biochem*. 1997; 845:838–45.
14. Gibbs HL, Sanz L, Chiocchi JE, Farrell TM, Calvete JJ. Proteomic analysis of ontogenetic and diet-related changes in venom composition of juvenile and adult Dusky Pigmy rattlesnakes (*Sistrurus miliaris barbouri*). *J Proteomics*. 2011; 74(10):2169–79. <https://doi.org/10.1016/j.jprot.2011.06.013> PMID: [21722760](#)
15. Chippaux J-P, Williams V, White J. Snake venom variability: methods of study, results and interpretation. *Toxicon*. 1991; 29(11):1279–303. PMID: [1814005](#)
16. Massey DJ, Calvete JJ, Sánchez EE, Sanz L, Richards K, Curtis R, et al. Venom variability and envenoming severity outcomes of the *Crotalus scutulatus scutulatus* (Mojave rattlesnake) from Southern Arizona. *J Proteomics*. 2012; 75(9):2576–87. <https://doi.org/10.1016/j.jprot.2012.02.035> PMID: [22446891](#)
17. Pla D, Sanz L, Sasa M, Acevedo ME, Dwyer Q, Durban J, et al. Proteomic analysis of venom variability and ontogeny across the arboreal palm-pitvipers (genus *Bothriechis*). *J Proteomics*. 2017; 152:1–12. <https://doi.org/10.1016/j.jprot.2016.10.006> PMID: [27777178](#)
18. de Morais-Zani K, Grego KF, Tanaka AS, Tanaka-Azevedo AM. Proteomic analysis of the ontogenetic variability in plasma composition of juvenile and adult *Bothrops jararaca* snakes. *Int J Proteomics*. 2013;2013.

19. Alape-Girón A, Sanz L, Escolano J, Flores-Díaz M, Madrigal M, Sasa M, et al. Snake venomomics of the lancehead pitviper *Bothrops asper*: geographic, individual, and ontogenetic variations. *J Proteome Res*. 2008; 7(8):3556–71. <https://doi.org/10.1021/pr800332p> PMID: 18557640
20. Menezes MC, Furtado MF, Travaglia-Cardoso SR, Camargo ACM, Serrano SMT. Sex-based individual variation of snake venom proteome among eighteen *Bothrops jararaca* siblings. *Toxicon*. 2006; 47(3):304–12. PMID: 16373076
21. Zelanis A, Tashima AK, Rocha MMT, Furtado MF, Camargo ACM, Ho PL, et al. Analysis of the ontogenetic variation in the venom proteome/peptidome of *Bothrops jararaca* reveals different strategies to deal with prey. *J Proteome Res*. 2010; 9(5):2278–91. <https://doi.org/10.1021/pr901027r> PMID: 20146532
22. Fontana F. Traité sur le venin de la vipere sur les poisons americains sur le laurier-cerise et sur quelques autres poisons végetaux: on y a joint des observations sur la structure primitive du corps animal. Differentes expériences sur la reproduction des nerfs et l. Vol. 1. chez Nyon l'Ainé; 1781.
23. Guyon J. Le Venin de Serpents Exerce-t-il sur Eux-mêmes l'Action Qu'il Exerce sur D'autres Animaux. Animaux Venimeux Venins La Fonct Venimeuse chez tous les Animaux; les Appar Venimeux. 1861;744.
24. Phisalix C, Bertrand G. Recherches sur l'immunité du hérisson contre le venin de vipère. *CR Soc Biol*. 1895; 47(10):639–41.
25. Poran NS, Coss RG, Benjamini ELI. Resistance of California ground squirrels (*Spermophilus beecheyi*) to the venom of the northern Pacific rattlesnake (*Crotalus viridis oreganus*): a study of adaptive variation. *Toxicon*. 1987; 25(7):767–77. PMID: 3672545
26. Voss RS, Jansa SA. Snake-venom resistance as a mammalian trophic adaptation: lessons from didelphid marsupials. *Biol Rev*. 2012; 87(4):822–37. <https://doi.org/10.1111/j.1469-185X.2012.00222.x> PMID: 22404916
27. Jansa SA, Voss RS. Adaptive evolution of the venom-targeted vWF protein in opossums that eat pitvipers. *PLoS One*. 2011; 6(6):e20997. <https://doi.org/10.1371/journal.pone.0020997> PMID: 21731638
28. Ohana B, Fraenkelg Y, Gershonit M. Molecular dissection of cholinergic binding sites: How do snakes escape the effect of their own toxins? 1991; 179(1):648–54. PMID: 1883386
29. Burden SJ, Hartzell HC, Yoshikami D. Acetylcholine receptors at neuromuscular synapses: phylogenetic differences detected by snake alpha-neurotoxins. *Proc Natl Acad Sci*. 1975; 72(8):3245–9. <https://doi.org/10.1073/pnas.72.8.3245> PMID: 1081230
30. Gomes CM, Morais-Zani K de, Lu S, Buarque D de S, Braz GRC, Grego KF, et al. Differential transcript profile of inhibitors with potential anti-venom role in the liver of juvenile and adult *Bothrops jararaca* snake. *PeerJ*. 2017; 5:e3203. <https://doi.org/10.7717/peerj.3203> PMID: 28462021
31. Saúde M da S (BR). S de V em SP. Guia de Vigilância em Saúde—Volume Único. [Internet]. Brasília: Ministério da Saúde de Brasília; 2017. p. 705p. Available from: http://bvsm.s.saude.gov.br/publicacoes/guia_vigilancia_saude_2ed.pdf
32. BRASIL. Ministério da Saúde—FUNASA. Manual de Diagnóstico e Tratamento de Acidentes por Animais Peçonhentos. 2° ed. Brasília; 2001.
33. Serino-Silva C, Morais-Zani K, Toyama MH, de Oliveira Toyama D, Gaeta HH, Rodrigues CFB, et al. Purification and characterization of the first γ -phospholipase inhibitor (γ PLI) from *Bothrops jararaca* snake serum. *PLoS One*. 2018; 13(3):e0193105. <https://doi.org/10.1371/journal.pone.0193105> PMID: 29505564
34. Tanaka-Azevedo AM, Tanaka AS, Sano-Martins IS. A new blood coagulation inhibitor from the snake *Bothrops jararaca* plasma: isolation and characterization. *Biochem Biophys Res Commun* [Internet]. 2003 Sep 5 [cited 2014 Dec 17]; 308(4):706–12. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/12927776> PMID: 12927776
35. Tanaka-Azevedo AM, Torquato RJS, Tanaka AS, Sano-Martins IS. Characterization of *Bothrops jararaca* coagulation inhibitor (BjI) and presence of similar protein in plasma of other animals. *Toxicon*. 2004; 44(3):289–94. PMID: 15302535
36. WHO (World Health Organization). Manual of the international statistical classification of diseases, injuries, and causes of death. Sixth revision. 1949.
37. Dutra NC, Telles MP, Dutra DL, Silva Júnior NJ. Genetic diversity in populations of the viper *Bothrops moojeni* Hoge, 1966 in Central Brazil using RAPD markers. *Genet Mol Res*. 2008; 7(3):603–13. PMID: 18752187
38. Amorim FG, Costa TR, Baiwir D, De Pauw E, Quinton L, Sampaio SV. Proteopeptidomic, Functional and Immunoreactivity Characterization of *Bothrops moojeni* Snake Venom: Influence of Snake Gender on Venom Composition. *Toxins (Basel)*. 2018; 10(5):177.

39. Santoro ML, Sano-Martins IS, Fan HW, Cardoso JLC, Theakston RDG, Warrell DA. Haematological evaluation of patients bitten by the jararaca, *Bothrops jararaca*, in Brazil. *Toxicon*. 2008; 51(8):1440–8. <https://doi.org/10.1016/j.toxicon.2008.03.018> PMID: 18471839
40. Bradford MM, Dourado DM, Matias R, Barbosa-Ferreira M, da Silva BAK, Muller J de AI, et al. Proteo-peptidomic, Functional and Immunoreactivity Characterization of *Bothrops moojeni* Snake Venom: Influence of Snake Gender on Venom Composition. *Toxins (Basel)* [Internet]. 2008 Jul [cited 2014 Dec 17]; 32(1):1357–66. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/18620721>
41. Soares AM, Marcussi S, Stábéli RG, França SC, Giglio JR, Ward RJ, et al. Structural and functional analysis of BmjMIP, a phospholipase A2 myotoxin inhibitor protein from *Bothrops moojeni* snake plasma. *Biochem Biophys Res Commun*. 2003; 302(2):193–200. PMID: 12604331
42. de Farias IB, de Morais-Zani K, Serino-Silva C, Sant'Anna SS, da Rocha MMT, Grego KF, et al. Functional and proteomic comparison of *Bothrops jararaca* venom from captive specimens and the Brazilian Bothropic Reference Venom. *J Proteomics*. 2018; 174:36–46. <https://doi.org/10.1016/j.jprot.2017.12.008> PMID: 29275044
43. Bradford MM. *Bradford, M. M.* *Anal Biochem*. 1976; 72:248. PMID: 942051
44. LAEMMLI UK. Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4. *Nature* [Internet]. 1970 Aug 15 [cited 2014 Jul 10]; 227(5259):680–5. Available from: <http://dx.doi.org/10.1038/227680a0> PMID: 5432063
45. Hanna SL, Sherman NE, Kinter MT, Goldberg JB. Comparison of proteins expressed by *Pseudomonas aeruginosa* strains representing initial and chronic isolates from a cystic fibrosis patient: an analysis by 2-D gel electrophoresis and capillary column liquid chromatography–tandem mass spectrometry. *Microbiology*. 2000; 146(10):2495–508.
46. de Silva AP. Analytical chemistry: sense and versatility. *Nature*. 2007; 445(7129):718. PMID: 17301777
47. Pedrosa AP, Souza AP, Dornellas APS, Oyama LM, Nascimento CMO, Santos GMS, et al. Intrauterine growth restriction programs the hypothalamus of adult male rats: integrated analysis of proteomic and metabolomic data. *J Proteome Res*. 2017; 16(4):1515–25. <https://doi.org/10.1021/acs.jproteome.6b00923> PMID: 28314371
48. Abreu TF, Sumitomo BN, Nishiyama MY Jr, Oliveira UC, Souza GHMF, Kitano ES, et al. Peptidomics of *Acanthoscurria gomesiana* spider venom reveals new toxins with potential antimicrobial activity. *J Proteomics*. 2017; 151:232–42. <https://doi.org/10.1016/j.jprot.2016.07.012> PMID: 27436114
49. Distler U, Kuharev J, Navarro P, Tenzer S. Label-free quantification in ion mobility-enhanced data-independent acquisition proteomics. *Nat Protoc*. 2016 Apr; 11(4):795–812. <https://doi.org/10.1038/nprot.2016.042> PMID: 27010757
50. Silva JC, Gorenstein M V, Li G-Z, Vissers JPC, Geromanos SJ. Absolute quantification of proteins by LCMSE a virtue of parallel MS acquisition. *Mol Cell Proteomics*. 2006; 5(1):144–56. PMID: 16219938
51. Perez-Riverol Y, Csordas A, Bai J, Bernal-Llinares M, Hewapathirana S, Kundu DJ, et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data. *Nucleic Acids Res*. 2018; 47(D1):D442–50.
52. Harlow E, Lane D. *Antibodies: A Laboratory Manual* [Internet]. 1988 [cited 2015 May 4]. Available from: <http://books.google.com.br/books/about/Antibodies.html?id=0p29pFaLwR8C&pgis=1>
53. Váchová L, Moravcová J. Two microassays for determination of a wide range of proteolytic activities using Azocoll as substrate. *Biochem Mol Biol Int*. 1993; 30(2):311–8. PMID: 8364412
54. Antunes TC, Yamashita KM, Barbaro KC, Saiki M, Santoro ML. Comparative analysis of newborn and adult *Bothrops jararaca* snake venoms. *Toxicon*. 2010; 56(8):1443–58. <https://doi.org/10.1016/j.toxicon.2010.08.011> PMID: 20816886
55. Holzer M, Mackessy SP. An aqueous endpoint assay of snake venom phospholipase A2. *Toxicon* [Internet]. 1996 Oct [cited 2014 Dec 18]; 34(10):1149–55. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/8931255> PMID: 8931255
56. Kishimoto M, Takahashi T. A spectrophotometric microplate assay for L-amino acid oxidase. *Anal Biochem*. 2001; 298(1):136–9. PMID: 11673909
57. Theakston RDG, Reid HA. Development of simple standard assay procedures for the characterization of snake venoms. *Bull World Health Organ* [Internet]. 1983 Jan [cited 2014 Dec 18]; 61(6):949–56. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2536230&tool=pmcentrez&rendertype=abstract> PMID: 6609011
58. Kondo H, Kondo S, Kezawa H, Murata R, Ohsaka A. Studies on the quantitative method for determination of hemorrhagic activity of Habu snake venom. *Japanese J Med Sci Biol*. 1960; 13(1–2):43–51.
59. Gutiérrez J, Gené J, Rojas G, Cerdas L. Neutralization of proteolytic and hemorrhagic activities of Costa Rican snake venoms by a polyvalent antivenom. *Toxicon*. 1985; 23(6):887–93. PMID: 3913055

60. Silles Villarroel M. Padronização da Titulação da Atividade Tóxica de Venenos Botrópicos em camundongos. *Mem Inst Butantan*. 1978; 42:311–23.
61. Finney DJ. *Probit Analysis*: 3d Ed. Cambridge University Press; 1971.
62. Valente RH, Dragulev B, Perales J, Fox JW, Domont GB. BJ46a, a snake venom metalloproteinase inhibitor. Isolation, characterization, cloning and insights into its mechanism of action. *Eur J Biochem* [Internet]. 2001 May [cited 2014 Dec 17]; 268(10):3042–52. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/11358523> PMID: 11358523
63. McCleary RJR, Sridharan S, Dunstan NL, Mirtschin PJ, Kini RM. Proteomic comparisons of venoms of long-term captive and recently wild-caught Eastern brown snakes (*Pseudonaja textilis*) indicate venom does not change due to captivity. *J Proteomics*. 2016; 144:51–62. <https://doi.org/10.1016/j.jprot.2016.05.027> PMID: 27240975
64. Perchuc AM, Menin L, Stöcklin R, Bühler B, Schöni R. The Potential of *Bothrops moojeni* Venom in the Field of Hemostasis. *Pathophysiol Haemost Thromb*. 2005; 34(4–5):241–5. PMID: 16707935
65. Zelanis A, Menezes MC, Kitano ES, Liberato T, Tashima AK, Pinto AFM, et al. Proteomic identification of gender molecular markers in *Bothrops jararaca* venom. *J Proteomics*. 2016; 139:26–37. <https://doi.org/10.1016/j.jprot.2016.02.030> PMID: 26941108
66. Nicolau CA, Carvalho PC, Junqueira-de-Azevedo ILM, Teixeira-Ferreira A, Junqueira M, Perales J, et al. An in-depth snake venom proteopeptidome characterization: Benchmarking *Bothrops jararaca*. *J Proteomics*. 2016;
67. Harris JB, Scott-davey T. Secreted Phospholipases A2 of Snake Venoms: Effects on the Peripheral Neuromuscular System with Comments on the Role of Phospholipases A2 in Disorders of the CNS and Their Uses in Industry. 2013;2533–71. <https://doi.org/10.3390/toxins5122533> PMID: 24351716
68. Richards DP, Barlow A, Wüster W. Toxicon Venom lethality and diet: Differential responses of natural prey and model organisms to the venom of the saw-scaled vipers (*Echis*). *Toxicon* [Internet]. 2012; 59(1):110–6. Available from: <https://doi.org/10.1016/j.toxicon.2011.10.015> PMID: 22079297
69. Prior KA, Gibbs HL, Weatherhead PJ. Population genetic structure in the black rat snake: implications for management. *Conserv Biol*. 1997; 11(5):1147–58.
70. Melgarejo AR, Cardoso JLC, França FOS. Serpentes peçonhentas do Brasil. *Cardoso, LC al Animais Peçonhentos no Bras Biol clínica e Ter dos Acid São Paulo Savier*. 2003;33–61.
71. Andrade D V, Abe AS, Dos Santos MC. Is the venom related to diet and tail color during *Bothrops moojeni* ontogeny? *J Herpetol*. 1996;285–8.
72. Queiroz GP, Pessoa LA, Portaro FC V, Maria de Fátima DF, Tambourgi D V. Interspecific variation in venom composition and toxicity of Brazilian snakes from *Bothrops* genus. *Toxicon*. 2008; 52(8):842–51. <https://doi.org/10.1016/j.toxicon.2008.10.002> PMID: 18983867
73. Sousa LF, Nicolau CA, Peixoto PS, Bernardoni JL, Oliveira SS, Portes-Junior JA, et al. Comparison of phylogeny, venom composition and neutralization by antivenom in diverse species of bothrops complex. *PLoS Negl Trop Dis*. 2013; 7(9):e2442. <https://doi.org/10.1371/journal.pntd.0002442> PMID: 24069493
74. Zancolli G, Sanz L, Calvete JJ, Wüster W. Venom On-a-Chip: A Fast and Efficient Method for Comparative Venomics. *Toxins (Basel)*. 2017; 9(6):179.
75. Pereira AZP. Análise da variabilidade ontogenética do veneno de *Bothrops insularis* (Amaral, 1921): implicações adaptativas aos itens alimentares. *Inst Biociências, Dep Fisiol* [Internet]. 2006; 104. Available from: file:///C:/Documents and Settings/Biblio_Herpeto/My Documents/Banco de dados Mendeley/V.1.2/Pereira/2006/Pereira_2006.pdf
76. Calvete JJ, Sanz L, Pérez A, Borges A, Vargas AM, Lomonte B, et al. Snake population venomics and antivenomics of *Bothrops atrox*: Paedomorphism along its transamazonian dispersal and implications of geographic venom variability on snakebite management. *J Proteomics*. 2011; 74(4):510–27. <https://doi.org/10.1016/j.jprot.2011.01.003> PMID: 21278006
77. Soares AM, Rodrigues VM, Homs-Brandeburgo MI, Toyama MH, Lombardi FR, Arni RK, et al. A rapid procedure for the isolation of the Lys-49 myotoxin II from *Bothrops moojeni* (caissaca) venom: biochemical characterization, crystallization, myotoxic and edematogenic activity. *Toxicon*. 1998; 36(3):503–14. PMID: 9637370
78. de Roodt AR, Litwin S, Vidal JC. Hemorrhagic activity of *Bothrops* venoms determined by two different methods and relationship with proteolytic activity on gelatin and lethality. *Toxicon*. 2003; 41(8):949–58. PMID: 12875868
79. Assakura MT, Reichl AP, Asperti MCA, Mandelbaum FR. Isolation of the major proteolytic enzyme from the venom of the snake *Bothrops moojeni* (caissaca). *Toxicon*. 1985; 23(4):691–706. PMID: 3933145

80. Campos LB, Pucca MB, Roncolato EC, Bertolini TB, Netto JC, Barbosa JE. In vitro comparison of enzymatic effects among Brazilian *Bothrops* spp. venoms. *Toxicon*. 2013; 76:1–10. <https://doi.org/10.1016/j.toxicon.2013.08.063> PMID: 23998940
81. Bregge-Silva C, Nonato MC, de Albuquerque S, Ho PL, de Azevedo ILMJ, Diniz MRV, et al. Isolation and biochemical, functional and structural characterization of a novel L-amino acid oxidase from *Lachesis muta* snake venom. *Toxicon*. 2012; 60(7):1263–76. <https://doi.org/10.1016/j.toxicon.2012.08.008> PMID: 22963728
82. Izidoro LFM, Sobrinho JC, Mendes MM, Costa TR, Grabner AN, Rodrigues VM, et al. Snake venom L-amino acid oxidases: trends in pharmacology and biochemistry. *Biomed Res Int*. 2014;2014.
83. Naumann GB, Silva LF, Silva L, Faria G, Richardson M, Evangelista K, et al. Cytotoxicity and inhibition of platelet aggregation caused by an L-amino acid oxidase from *Bothrops leucurus* venom. *Biochim Biophys Acta (BBA)-General Subj*. 2011; 1810(7):683–94.
84. Souza DHF, Eugenio LM, Fletcher JE, Jiang M-S, Garratt RC, Oliva G, et al. Isolation and structural characterization of a cytotoxic L-amino acid oxidase from *Agkistrodon contortrix laticinctus* snake venom: preliminary crystallographic data. *Arch Biochem Biophys*. 1999; 368(2):285–90. PMID: 10441379
85. Gutiérrez J, Lomonte B. Phospholipase A 2 myotoxins from *Bothrops* snake venoms. *Toxicon*. 1995; 33(11):1405–24. PMID: 8744981
86. Gutiérrez JM, Rucavado A. Snake venom metalloproteinases: their role in the pathogenesis of local tissue damage. *Biochimie*. 2000; 82(9):841–50.
87. Ownby CL. Structure, function and biophysical aspects of the myotoxins from snake venoms. *Toxin Rev*. 1998; 17(2):213–38.
88. Sousa L, Zdenek C, Dobson J, Coimbra F, Gillett A, Del-Rei T, et al. Coagulotoxicity of *Bothrops* (lancehead pit-vipers) venoms from Brazil: differential biochemistry and antivenom efficacy resulting from prey-driven venom variation. *Toxins (Basel)*. 2018; 10(10):411.
89. Zhang Y. Why do we study animal toxins? *Zool Res*. 2015; 36(4):183. <https://doi.org/10.13918/j.issn.2095-8137.2015.4.183> PMID: 26228472
90. World Health Organization WHO. WHO guidelines for the production, control and regulation of snake antivenom immunoglobulins. Geneva WHO. 2010;134.
91. Hatakeyama DM, de Morais-Zani K, Serino-Silva C, Grego KF, Sant'Anna SS, Fernandes W, et al. Examination of biochemical and biological activities of *Bothrops jararaca* (Serpentes: Viperidae; Wied-Neuwied 1824) snake venom after up to 54 years of storage. *Toxicon*. 2018; 141:34–42. <https://doi.org/10.1016/j.toxicon.2017.11.011> PMID: 29179989
92. Silva-de-França F, Villas-Boas IM, de Toledo Serrano SM, Cogliati B, de Andrade Chudzinski SA, Lopes PH, et al. *Naja annulifera* Snake: New insights into the venom components and pathogenesis of envenomation. *PLoS Negl Trop Dis*. 2019; 13(1):e0007017. <https://doi.org/10.1371/journal.pntd.0007017> PMID: 30657756
93. Sanchez EF, Freitas T V, Ferreira-Alves DL, Velarde DT, Diniz MR, Cordeiro MN, et al. Biological activities of venoms from South American snakes. *Toxicon*. 1992; 30(1):95–103. PMID: 1595082
94. Tanaka GD, Maria de Fátima DF, Portaro FC V, Sant'Anna OA, Tambourgi D V. Diversity of *Micrurus* snake species related to their venom toxic effects and the prospective of antivenom neutralization. *PLoS Negl Trop Dis*. 2010; 4(3):e622. <https://doi.org/10.1371/journal.pntd.0000622> PMID: 20231886
95. Saldarriaga MM, Otero R, Núñez V, Toro MF, Díaz A, Gutiérrez JM. Ontogenetic variability of *Bothrops atrox* and *Bothrops asper* snake venoms from Colombia. *Toxicon*. 2003; 42(4):405–11. PMID: 14505941